%0 English Abstract
%T [Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].
%A Fourmond S
%A Gutierrez B
%A Gourin MP
%A Delaumenie S
%A Ly KH
%A Fourmond S
%A Gutierrez B
%A Gourin MP
%A Delaumenie S
%A Ly KH
%J Rev Med Interne
%V 43
%N 5
%D May 2022
%M 35219509
%F 0.885
%R 10.1016/j.revmed.2022.01.007
%X <B>BACKGROUND: </B>Apremilast is a phosphodiesterase 4 inhibitor used in psoriasis and psoriatic arthritis Recently, this treatment has received marketing authorization for severe and refractory oral aphthosis in Behçet's disease. Idiopathic recurrent aphthous stomatitis (RAS) outside of Behçet's disease is often difficult to treat and can affect patients' quality of life.<BR><B>METHODS: </B>We report our experience with the use of apremilast in two 49-year-old patients with refractory oral aphthosis not related to Behçet's disease or another etiology. In both cases, a combination of apremilast with low-dose prednisone controlled the idiopathic RAS within a few weeks.<BR><B>CONCLUSIONS: </B>Apremilast, which already has marketing authorization for Behçet's disease, also appears to be effective in RAS.